NAGESHWARA V. DASARI to Cetuximab
This is a "connection" page, showing publications NAGESHWARA V. DASARI has written about Cetuximab.
Connection Strength
0.048
-
Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. Clin Colorectal Cancer. 2014 Sep; 13(3):164-71.
Score: 0.026
-
Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. Invest New Drugs. 2013 Apr; 31(2):345-54.
Score: 0.022